Leukemias PDX

Acute myelogenous leukemia (AML), which accounts for nearly 70% of adult leukemias, is one of the most challenging leukemias to cure. FLT3 (FMS-like tyrosine kinase 3), also known as Flk2/CD135, is a type III receptor tyrosine kinase (RTK) that is critical for the survival, proliferation, and differentiation of hematopoietic cells. FLT3 gene mutations are a common genetic variant in AML (approximately 30%) and are associated with a poor clinical prognosis and susceptibility to relapse. Consequently, FLT3 inhibitor research is critical for AML treatment. The construction of the AML-PDX model requires additional human cytokines to help AML leukemia cells escape residual innate immune surveillance in mice in a specific supportive stromal cell milieu and subsequently home and expand in mice. GemPharmatech's NCG-M mouse strain outperforms a conventional, severely immunodeficient mouse without human cytokine assistance in terms of modeling efficiency. AML-PDX models with FLT3 mutations have been developed and are suitable for drug sensitivity testing as well as preclinical efficacy evaluation of various AML therapies.

图片1.png

Figure 1. The hCD45+ cells percentage in peripheral blood increased gradually after AML-PDX modeling. The NCG-M mouse strain outperformed the NCG strain in terms of modeling efficiency.

图片2.png

Figure 2. Characteristic markers such as hCD45+, hCD33+, and hCD135+ (FLT3) were identified in the peripheral blood of mice at various stages after the AML-PDX models were passaged. Lower inoculum doses successfully amplified AML-PDX models in the NCG-M strain, and the efficacy and quality of modeling were dose-dependent.

TALK WITH OUR EXPERTS

*

AREA OF INTEREST

Oncology Autoimmune Metabolism Neuroscience Cardiovascular Gut Microbiota Aging Rare Diseases Other

*

How did you hear about us?

Search Engine Social Media Email Conference Colleague Other

GemPharmatechは、お客様のプライバシーを保護し、尊重することをお約束します。お客様の個人情報は、アカウントの管理およびお客様からご要望いただいた製品やサービスの提供に利用いたします。時折、当社の製品やサービスに関する情報や、お客様に興味があるかもしれない他のコンテンツについてご連絡差し上げたいと考えております。お客様にこの目的をご連絡し、ご同意いただける場合は、以下の方法でお客様にどのようにご連絡させていただけるかをお知らせください。

GemPharmatechからの他のご連絡を受けることに同意します。

ご希望のコンテンツを提供するために、お客様の個人データを保存および処理する必要があります。この目的でお客様の個人データを保存することにご同意いただける場合は、以下のチェックボックスをクリックしてください。

GemPharmatechに個人データの保存および処理について同意します。

同意をいつでも撤回する権利があります。購読解除の詳細情報、当社のプライバシーに関する実践、およびお客様のプライバシーを保護し尊重するための取り組みについての詳細については、当社のプライバシーポリシーをご覧ください。